Dates: 5-8 May 2019
Location: Ascona, Switzerland
Abstract submission deadline: 1 Feb 2019
Benefitting from tremendous advances in large-scale ‘omics’ technologies, immune phenotyping and genome engineering, novel integrated workflows are providing unprecedented insights into the networks, pathways and systems that govern human health and disease, thus enabling their successful therapeutic manipulation. The conference will begin with insights into recent strategies and concepts in the area of therapeutic protein engineering, rational vaccine design and -delivery.
Next, advances in high-throughput methods such as (single-cell) sequencing and microfluidics will be discussed which devise general construction principles of the adaptive immune system and provide information on immune status upon perturbation, as well as on potential disease-specific biomarkers. The meeting will then move on to shed light on the potential and risks of adoptive immune cell transfer therapies that are on the rise due to the current revolution in precise genome engineering. Critical to clinical progress is the translation of foundational synthetic and systems immunology research into novel therapies. A dedicated session centered on that topic in the field of cancer immunotherapy and infectious diseases will conclude the meeting.
Some funds are available for a contribution towards travel expenses of MSc and PhD students to attend the conference. The available amount will be determined individually based on the available funds and the number of successful candidates. This is only open to those who submit abstracts.
The conference wil be limited to a maximum of 120 participants.
Find out more on the conference website.
